We examined the influence of chronic treatment with ANG-(1-7) on development of hypertension and end-organ damage in spontaneously hypertensive rats (SHR) chronically treated with the nitric oxide synthesis inhibitor L-NAME (SHR-L-NAME). L-NAME administered orally (80 mg/l) for 4 wk significantly elevated mean arterial pressure (MAP) compared with SHR controls drinking regular water (269 +/- 10 vs. 196 +/- 6 mmHg). ANG-(1-7) (24 microg x kg(-1) x h(-1)) or captopril (300 mg/l) significantly attenuated the elevation in MAP due to L-NAME (213 +/- 7 and 228 +/- 8 mmHg, respectively), and ANG-(1-7) + captopril completely reversed the L-NAME-dependent increase in MAP (193 +/- 5 mmHg). L-NAME-induced increases in urinary protein were significantly lower in ANG-(1-7)-treated animals (226 +/- 6 vs. 145 +/- 12 mg/day). Captopril was more effective (96 +/- 12 mg/day), and there was no additional effect of captopril + ANG-(1-7) (87 +/- 5 mg/day). The abnormal vascular responsiveness to endothelin-1, carbachol, and sodium nitroprusside in perfused mesenteric vascular bed of SHR-L-NAME was improved by ANG-(1-7) or captopril, with no additive effect of ANG-(1-7) + captopril. In isolated perfused hearts, recovery of left ventricular function from 40 min of global ischemia was significantly better in ANG-(1-7)- or captopril-treated SHR-L-NAME, with additive effects of combined treatment. The beneficial effects of ANG-(1-7) on MAP and cardiac function were inhibited when indomethacin was administered with ANG-(1-7), but indomethacin did not reverse the protective effects on proteinuria or vascular reactivity. The protective effects of the ANG-(1-7) analog AVE-0991 were qualitatively comparable to those of ANG-(1-7) but were not improved over those of captopril alone. Thus, during reduced nitric oxide availability, ANG-(1-7) attenuates development of severe hypertension and end-organ damage; prostaglandins participate in the MAP-lowering and cardioprotective effects of ANG-(1-7); and additive effects of captopril + ANG-(1-7) on MAP, but not proteinuria or endothelial function, suggest common, as well as different, mechanisms of action for the two treatments. Together, the results provide further evidence of a role for ANG-(1-7) in protective effects of angiotensin-converting enzyme inhibition and suggest dissociation of factors influencing MAP and those influencing end-organ damage.

Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292: H666 -H672, 2007; doi:10.1152/ajpheart.00372.2006.-The aim of this study was to test the hypothesis that treatment with angiotensin-(1-7) [ANG-(1-7)] or ANG-(1-7) nonpeptide analog AVE-0991 can produce protection against diabetes-induced cardiovascular dysfunction. We examined the influence of chronic treatment (4 wk) with ANG-(1-7) (576 g ⅐ kg Ϫ1 ⅐ day Ϫ1 ip) or AVE-0991 (576 g ⅐ kg Ϫ1 ⅐ day Ϫ1 ip) on proteinuria, vascular responsiveness of isolated carotid and renal artery ring segments and mesenteric bed to vasoactive agonists, and cardiac recovery from ischemia-reperfusion in streptozotocin-treated rats (diabetes). Animals were killed 4 wk after induction of diabetes and/or treatment with ANG-(1-7) or AVE-0991. There was a significant increase in urine protein (231 Ϯ 2 mg/24 h) in diabetic animals compared with controls (88 Ϯ 6 mg/24 h). Treatment of diabetic animals with ANG-(1-7) or AVE-0991 resulted in a significant reduction in urine protein compared with vehicle-treated diabetic animals (183 Ϯ 16 and 149 Ϯ 15 mg/24 h, respectively). Treatment with ANG-(1-7) or AVE-0991 also prevented the diabetes-induced abnormal vascular responsiveness to norepinephrine, endothelin-1, angiotensin II, carbachol, and histamine in the perfused mesenteric bed and isolated carotid and renal arteries. In isolated perfused hearts, recovery of left ventricular function from 40 min of global ischemia was significantly better in ANG-(1-7)-or AVE-0991-treated animals. These results suggest that activation of ANG-(1-7)-mediated signal transduction could be an important therapeutic strategy to reduce cardiovascular events in diabetic patients. diabetes; AVE-0991; vascular dysfunction; carotid artery DIABETES MELLITUS IS A MAJOR debilitating disease affecting millions worldwide. The quality of life of patients with diabetes is largely determined by the complications rather than the primary disease. Among these, micro-and macrovascular dysfunctions are probably the most dominant factors because they result in a three-to fivefold increase in deaths in diabetics compared with the normal population. Diabetes-induced cardiovascular dysfunction is evidenced clinically by accelerated atherosclerosis, retinopathy, nephropathy, occlusive vascular disease, and hypertension (18,26,34). Alterations within the renin-angiotensin system are considered to be important for the development of diabetic complications, particularly diabetic renal disease and hypertension (10,38,46,47). Suppression of angiotensin II (ANG II) synthesis or activity can prevent or slow the progression of diabetes-induced cardiovascular complications. Indeed, angiotensin-converting enzyme (ACE) inhibitors and ANG II receptor blockers have become an integral part of any therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes (10, 35).Angiotensin-(1-7) [ANG-(1-7)] is a vasodilator ...

No abstract

1 The purpose of this study was to examine the effect of inhibition of the formation of cytochrome P450 metabolites of arachidonic acid with 1-aminobenzotriazole (ABT) on the development of hypertension and end-organ damage in spontaneously hypertensive rats (SHR) chronically treated with nitric oxide synthesis inhibitor L-NAME (SHR-L-NAME). 2 Administration of L-NAME in drinking water (80 mg l(-1)) to SHR for 3 weeks significantly elevated mean arterial blood pressure (MABP) (223 +/- 4 mmHg) as compared to SHR controls drinking regular water (165 +/- 3 mmHg). The administration of ABT (50 mg kg(-1) i.p. alt diem) for 6 days significantly attenuated elevation of blood pressure in SHR-L-NAME (204 +/- 4 mmHg). 3 L-NAME-induced increase in urine volume and protein was significantly lower in ABT-treated animals. 4 The impaired vascular responsiveness to noradrenaline and isoprenaline in the perfused mesenteric vascular bed of SHR-L-NAME-treated animals was significantly improved by ABT treatment. 5 Morphological studies of the kidneys and hearts showed that treatment with ABT minimized the extensive arterial fibrinoid necrosis, arterial thrombosis, significant narrowing of arterial lumen with marked arterial hyperplastic arterial changes that were observed in vehicle treated SHR-L-NAME. 6 In isolated perfused hearts, recovery of left ventricular function from 40 min of global ischaemia was significantly better in ABT-treated SHR-L-NAME. 7 These results suggest that in hypertensive individuals with endothelial dysfunction and chronic NO deficiency, inhibitors of 20-HETE synthesis may be able to attenuate development of high blood pressure and end-organ damage.

Ethane exhalation was increased in male Sprague-Dawley rats following a single intraperitoneal (IP) injection of Aroclor 1254 (500 mg/kg). In the first 2 weeks following Aroclor 1254 treatment, the increase in ethane exhalation was due to an inhibition of metabolism of endogenous ethane rather than to an increase in ethane production. In weeks 3 and 4 following Aroclor 1254 administration, metabolic clearance of ethane returned to and exceeded control levels, while ethane production increased to approximately twice the control rates (day 30). The HPLC determination of in situ hepatic malondialdehyde levels revealed a 2-fold increase in malondialdehyde content on day 30 following the Aroclor 1254 injection. Further, parallel increases in in situ malondialdehyde levels and ethane production rates were also found 30 days following a single IP injection of 3,3',4,4'-tetrachlorobiphenyl, 2,3,4,4',5-pentachlorobiphenyl and 2,2',4,4',5,5'-hexachlorobiphenyl (300 mumol/kg). These effects were not reflected in increased diene conjugation. Redox state of the liver was largely unaffected, as evidenced by the relative concentrations of reduced and oxidized NADPH. However, minor changes in reduced and oxidized glutathione were noted.

No abstract

No abstract

Together the two rat kidneys accumulated a total of 31.7 +/- 1.6% of the intravenously injected amount of 7 nmoles egg-white-lysozyme (measured as iodine 125 lysozyme) within 10 min. The low molecular weight protein lysozyme and other basic substances were injected simultaneously in order to evaluate whether these basic substances can inhibit the renal lysozyme accumulation. The inhibitory effect of various basic compounds was dose-dependent with a maximal reduction of lysozyme accumulation to 11.7 +/- 0.08%. The basic substances could be divided into three groups depending upon the micromolar amount injected at which a 50% inhibition was achieved (0.3-1.2 micromoles: cytochrome C, ribonuclease; 10.9 micromoles; spermine; 501-688 micromoles: L-arginine, L-lysine). The neutral myoglobin had no effect on renal lysozyme accumulation. The inhibitory potency appeared to increase with increasing molecular weight and pI value of the substance tested. Microperfusion experiments of proximal convoluted tubules of rat kidney revealed that luminal reabsorption of the basic lysozyme can be inhibited by the basic protein cytochrome C in a dose-dependent fashion. In these experiments the perfusion solution contained 57 micromol .l-1 lysozyme, an intratubular lysozyme concentration at which the tubular lysozyme reabsorption was found to be about 80% saturated. A 50% inhibition of the tubular endocytic lysozyme reabsorption was achieved a cytochrome C concentration of 102 micromol.l-1.